Hemlibra for mild hemophilia A patients
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial studies Hemlibra (emicizumab) in people with mild congenital hemophilia A to see how well it works and what safety issues may occur. It may help reduce bleeding in patients who meet the study’s specific health and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male and between ages 5 and 45
- You must have mild congenital hemophilia A (baseline FVIII between 5% and 30%) and no FVIII inhibitor history
- Your BMI must be under 30
- You need recent records of bleeding episodes and any bleeding treatments used in the 12 months before joining
- You must be able to attend scheduled visits and complete bleed logs/questionnaires/activity tracking during the study
- You must pass basic liver, kidney, and blood test thresholds at screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adjusting emicizumab (Hemlibra) doses based on your body's drug levels can safely maintain good bleed control in people with hemophilia A who have been on the drug for at least a year.
This trial compares two low-dose prophylactic treatments for severe hemophilia A. Patients receive either low-dose emicizumab or low-dose factor VIII to see which works better for preventing bleeding episodes.
This trial uses ultrasound to check if healthy joints in people with hemophilia A develop damage while being treated with emicizumab (Hemlibra). It looks at elbows, knees, and ankles over time to see if the medicine prevents joint problems.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This trial tests emicizumab, a medicine given under the skin, to see how it works in children with hemophilia A. It aims to help control bleeding, no matter if they have inhibitors or not.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Hear when a new Factor VIII Deficiency, Congenital trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.